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Abstract
Background: Gout treatment remains suboptimal. Identifying populations at risk of developing gout may provide
opportunities for prevention. Our aim was to assess the risk of incident gout associated with obesity, hypertension
and diuretic use.
Methods: We conducted a systematic review and meta-analysis of prospective and retrospective cohort studies in
adults (age ≥ 18 years) from primary care or the general population, exposed to obesity, hypertension or diuretic
use and with incident gout as their outcome.
Results: A total of 9923 articles were identified: 14 met the inclusion criteria, 11 of which contained data suitable
for pooling in the meta-analysis. Four articles were identified for obesity, 10 for hypertension and six for diuretic
use, with four, nine and three articles included respectively for each meta-analysis. Gout was 2.24 times more likely
to occur in individuals with body mass index ≥ 30 kg/m2 (adjusted relative risk 2.24 (95% confidence interval)
1.76–2.86). Hypertensive individuals were 1.64 (1.34–2.01) and 2.11 (1.64–2.72) times more likely to develop gout
as normotensive individuals (adjusted hazard ratio and relative risk respectively). Diuretic use was associated with
almost 2.5 times the risk of developing gout compared to no diuretic use (adjusted relative risk 2.39 (1.57–3.65)).
Conclusions: Obesity, hypertension and diuretic use are risk factors for incident gout, each more than doubling the
risk compared to those without these risk factors. Patients with these risk factors should be recognised by clinicians
as being at greater risk of developing gout and provided with appropriate management and treatment options.
Keywords: Gout, Systematic review, Meta-analysis, Rheumatology
Background
Gout affects 2.5% of adults in the UK, with prevalence and
incidence continuing to rise [1, 2]. The primary risk factor
for gout is an elevated serum urate level (hyperuricaemia),
leading to monosodium urate crystal deposition in and
around joints, acute attacks of crystal synovitis and progres-
sive joint damage [3]. Long-term treatment of gout involves
using urate-lowering therapies (ULT), typically allopurinol
[4] to inhibit xanthine oxidase, resulting in improved long-
term outcomes. Despite this, treatment use remains
suboptimal [5] and, therefore, identifying populations at
risk of developing gout, especially those in primary care
where the majority of patients with gout are managed, may
provide opportunities for primary prevention.
Body mass index (BMI) and hypertension have been
identified as risk factors for incident gout in a number of
large epidemiological studies [6], yet the magnitude of risk
varies between studies. Obesity promotes insulin resist-
ance which in turn reduces renal urate excretion resulting
in hyperuricaemia [7]. Hypertension predisposes to gout
by reducing renal urate excretion due to glomerular arteri-
olar damage and glomerulosclerosis. Diuretics are perhaps
the most well-known medications to be associated with
gout; they raise serum uric acid levels by increasing uric
acid reabsorption and decreasing uric acid secretion in the
kidneys. However, it has also been proposed that diuretic
use alone does not increase the risk of gout and that the
observed associated risk is due to the presence of co-
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morbidities which they are used to treat; commonly
hypertension, heart failure and renal failure [8]. Studying
obesity, hypertension and diuretic use and their associ-
ation with incident gout to elucidate the true nature and
magnitude is important because all three are common
and can be modified. We performed a systematic review
of cohort studies with the aim of deriving pooled esti-
mates of the risk of incident gout associated with obesity,
hypertension and diuretic use.
Methods
Literature search
We searched MEDLINE, Embase, CINAHL and the
Cochrane Library from their inception to March 2017. A
combination of free-text and medical subject heading
(MeSH) terms, or database-specific equivalents, were used
(Appendix 1). Reference lists of included articles were
searched for additional eligible articles.
Inclusion and exclusion criteria
The inclusion criteria were developed using the PICOS
framework [9]. The population of interest was adults aged
18 years or older. Studies which included participants
under the age of 18 years at cohort entry, but in whom
outcome was assessed in adulthood, were deemed to meet
this inclusion criterion. Articles were required to have
examined at least one of: obesity (BMI ≥ 30 kg/m2),
hypertension (self-reported, physician-diagnosed or study-
defined mmHg value) or diuretic use (self-reported or
reported in records) and their association with incident
gout, defined as the first recorded episode (i.e. a subse-
quent new diagnosis of gout). Articles which studied the
incidence of gout in specific hyperuricaemic populations
were excluded. Included articles had to be cohort studies,
prospective or retrospective and undertaken in primary
care or the general population.
No restrictions were imposed on language or the time
periods for publication, with medical literature databases
searched from inception. Where full articles could not be
obtained, these were requested from the corresponding
author.
Screening process
After duplicates had been removed from the initial search,
the titles and abstracts of all of the remaining articles were
screened by two authors (PLE and CH). Two authors
(PLE/CH and JAP) then independently reviewed the full
text of the remaining articles to decide on inclusion. Any
articles where there was disagreement about inclusion
were subsequently arbitrated over by a third author (ER).
Data extraction and quality assessment
Data were extracted from the full set of eligible articles by a
single author (PLE/CH) and also extracted independently
from a subset (50%) of the eligible articles by a second
author (JAP). If risk estimates were not reported in the
original articles, these were requested from the correspond-
ing author. Extracted variables included author, year and
title of publication, country in which the study took place,
the number of years of follow-up, baseline demographics of
participants which included age, gender and ethnicity, the
number of cases of incident gout, the study setting (primary
care or general population), exposure of interest and
method of definition used, the method of gout diagnosis
and the risk estimate of incident gout associated with that
particular exposure, and both unadjusted and adjusted
values were extracted if available. The methodological
quality of all eligible articles was assessed independently by
two authors (PLE/CH and JAP) using the cohort study
template of the Newcastle–Ottawa Scale (NOS). Funnel
plots were produced from the adjusted data points for each
meta-analysis to examine the extent of any publication bias.
Statistical analysis
Narrative synthesis was used to summarise the character-
istics of studies included in the systematic review. Esti-
mates were pooled for an individual risk factor if there
were a minimum of three values which met the criteria;
the exposure was measured in a similar manner and used
the same risk estimate (e.g. odds ratio (OR), relative risk
(RR), hazards ratio (HR)). Firstly, unadjusted or minimal
adjusted risk estimates were pooled for each individual
risk factor, and then the maximal multivariate-adjusted
risk estimates.
Pooled risk estimates were calculated using random-
effects meta-analysis. A random-effects model is considered
more appropriate for meta-analyses with the potential for
substantial heterogeneity. Quantifying the inconsistency
across studies was assessed using Cochran Q and I2
statistics. The DerSimonian and Laird random-effects
models were then used to calculate the pooled risk together
with associated 95% confidence intervals (CI). The meta-
analysis was performed using STATA 13.
Results
Search results
The search yielded a total of 9923 articles. Of these 3606
were duplicates and hence removed, leaving 6317 indi-
vidual publications to be screened by title and abstract.
Forty-nine articles could not be excluded by title and
abstract and had their full text reviewed. Thirty-five
articles were excluded (Appendix 2), 14 articles met the
inclusion criteria [10–23], no additional articles were
identified in their reference lists and a final 11 articles
contained data suitable for pooling in the meta-analysis
[11, 13–18, 22–25] (Fig. 1).
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Characteristics of included articles
Thirteen of the 14 articles included in the systematic
review used general populations, with one from primary
care [13] (Table 1). The majority were from the USA,
with the remaining four articles from the UK, Singapore
[22], Taiwan [18] and Tokelau (South Pacific island)
[10]. Sample sizes for the included articles ranged from
923 to 60,181, with the number of incident cases of gout
ranging from 43 to 1341. Two studies included only
male participants—one using a cohort of male health
professionals [14] and the other a sample of male med-
ical students [12]—and one study included an all-female
sample from the Atherosclerosis Risk in Communities
(ARIC) study [17]. The remaining 11 studies included
both men and women, although the sample in one study
was predominantly male (91%) [11]. There was a major-
ity of white participants (ranging from 62 to 100%) in
the nine articles which reported the ethnic composition
of their samples, with the exception of Prior et al. [10]
which examined 100% Tokelauan. Two studies included
participants who were aged under 18 years at study entry
[10, 16], two studies included those in their mid-twenties
(university students) [11, 12], seven studies included par-
ticipants in middle-older age [14, 15, 17, 18, 20, 22, 25],
one study included participants in older age [23] and two
studies included wide age ranges (18–89 years) [13, 21].
9,923
articles identified through database searches
MEDLINE: 2,198 
EMBASE: 7,379 
CINAHL: 248 
Cochrane Library: 98
3,606 
duplicate articles removed
6,317
articles screened using title & abstract
49
articles screened using full-text
6,268 
articles excluded
14
articles included in systematic review
35 
articles excluded
Not a cohort study: 22
Incident gout not assessed: 6
Not general population: 6
Based on an RCT: 1
11
articles included in meta-analysis
3 
articles excluded
Data unsuitable for pooling: 3
0 
articles included from reference 
list check
Fig. 1 Number of articles at each stage of the search and screening process
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Table 1 Characteristics of the included articles (n = 14)
Article Country Study setting
(study name)
Age
(years)
Gender Ethnicity Years of
follow-up
Ascertainment of exposure Ascertainment of gout
diagnosis
Prior et al.
1987 [10]
New Zealand
and Tokelau
Population
based
≥ 15 at
baseline,
≥ 18 at first
follow-up
Men and
women
included,
but numbers
not specified
100%
Tokelauan
Up to 14 Hypertension: measurement
of systolic and diastolic
blood pressure
History of ≥ 2 episodes
of podagra with redness
and swelling of first
metatarsophalangeal joint
Roubenoff
et al. (1991)
[11]a
USA Population
based
(medical
students)
(John
Hopkins
precursor
study)
Median 22 Men: 1216
(91%);
women:
121 (9%)
White:
1301 (97%);
non-white:
36 (3%)
40 Hypertension: self-reported
SBP > 160 mmHg or DBP
> 95 mmHg on two
questionnaires or
self-reported
anti-hypertensive
medication use
Self-report followed by
medical chart review
Hochberg
et al. (1995)
[12]a
USA Population
based
(medical
students)
(John
Hopkins
precursor
study)
White:
mean 26.1,
SD 1.8;
black: mean
29.0, SD 3.8
Men: 923
(100%)
White: 571
(62%);
black:
352 (38%)
26–34;
mean 29
Hypertension: self-reported
SBP > 160 mmHg or DBP
> 95 mmHg on two
questionnaires or
self-reported
anti-hypertensive
medication use
Self-report plus one of:
history of MSU crystals
or documented
tophus or use of
colchicine, probenecid
or allopurinol
Grodzicki
et al. (1997)
[13]a
UK Primary
care
(general
practice
hypertension
study)
18–65 Men: 1060
(50%);
women:
1068 (50%)
Not
reported
Average
8
Hypertension: not reported
Diuretic use: not reported
Diagnosed by GP
Choi et al.
(2005) [14]a
USA Population
based
(male
healthcare
professionals)
(health
professionals
follow-up
study)
40–75,
mean 54
Men: 47,150
(100%)
91% white 12 Obesity: self-reported
Hypertension: self-reported
physician-diagnosed
hypertension
Diuretic use: self-reported
Self-report followed by
ACR criteria (≥ 6/11 for
diagnosis of gout)
Bhole et al.
(2010) [15]a
USA Population
based
(Framington
heart study)
Men: mean 46,
SD 9; women:
mean 47, SD 9
Men: 1951
(44%);
women: 2476
(56%)
Not
reported
52;
median
28
Obesity: measured height
and weight, BMI calculated
Hypertension: average of
two readings SBP ≥ 140
mmHg or DBP ≥ 90 mmHg
Diuretic use: self-reported
Clinical diagnosis at any
follow-up study
examination
McAdams
DeMarco
et al.
(2011) [16]a
USA Population
based
(CLUE II
study)
13–87 at
baseline,
≥ 24 at
first
follow-up
Men: 6100
(39%);
women:
9433 (61%)
White:
15,533
(100%)
18 Obesity: self-reported Self-report
Maynard
et al.
(2012) [17]a
USA Population
based
(ARIC)
45–64 Women:
6263 (100%)
White:
4676 (75%);
black: 1587
(25%)
9 Obesity: self-reported Self-report
Chen et al.
(2012) [18]a
Taiwan Population
based
(health
insurance
database)
Men: mean
46, SD 9;
women:
mean
47, SD 9
Men: 60,181
(45%);
women:
72,375 (55%)
– Median
7.31
Hypertension: record
linkage
Record linkage:
diagnostic code of
gout from ICD-9 + 2×
prescriptions of
colchicine +
prescription of
urate-lowering drugs
McAdams-
DeMarco
et al. (2012)
[25]a
USA Population
based
(ARIC)
45–64;
mean 54,
SD 5.7
Men: 4709
(43%);
women:
6163 (57%)
White:
8538
(79%);
black:
2334 (21%)
9 Hypertension: self-report
of anti-hypertension
medications or measured
high blood pressure
Self-report
McAdams
DeMarco
USA Population
based
Men: 2445
(42%);
White:
3998 (69%);
9 Diuretic use: self-report Self-report
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The length of follow-up of participants ranged from 8 to
52 years.
From the 14 articles included in this review, 11
were used within the meta-analysis. Seven articles
were pooled as each had recorded a risk estimate for
at least one of the risk factors of interest using RR
(95% CI) and four articles were pooled based on their
use of HRs (95% CI). The risk estimates from the
remaining three articles were not sufficient to pool
risk estimates (Table 2).
The covariates which each article included in its
maximal adjustment model are described in detail in
Table 2; however, the majority of articles adjusted for
age, gender, co-morbidities, alcohol intake and food/
energy intake. Several adjustment models included
specific covariates; however, each of the three risk
factors of interest was typically adjusted for both of
the other two risk factors. Therefore, of the four
obesity articles, all adjusted for hypertension and
three adjusted for diuretic use; of the six hypertension
articles, five adjusted for BMI and two adjusted for
diuretic use; and finally, all three of the articles exam-
ining diuretic use as a risk factor for gout adjusted
for hypertension and BMI.
Quality appraisal of articles included in the meta-analysis
Three of the 11 studies (27%) included a specific sample
(male healthcare professionals (n = 1), medical students
(n = 2)) [11, 12, 14]. Six articles (55%) ascertained
exposure using a secure record or structured interview,
ranking as the highest quality approach [11, 13, 15, 17,
22, 23]. Eight articles (73%) specifically mentioned that
they had excluded participants with prevalent gout at
the beginning of the study [14–18, 22, 23, 25]. No
studies required the diagnosis of gout to be crystal
proven, two studies (18%) defined gout through clinical
diagnosis [13, 15] and, although the remaining nine
studies had defined a new gout diagnosis through self-
report, four of these additionally used the ACR criteria
[14] or a review of the medical records [11, 12, 22] to
support the definition. Three articles (27%) provided
unadjusted risk estimates only [11, 13, 23], with the
remaining articles providing results with adjustment for
at least two confounding factors. Eight articles (73%)
provided a description of those lost to follow-up [11, 12,
14–17, 22, 23] (Appendix 3). Funnel plots for each
meta-analysis did not demonstrate any discernible asym-
metry (Appendix 4).
Obesity
For obesity, four articles met the inclusion criteria, all of
which were suitable for pooling as all had defined obesity
as BMI ≥ 30 kg/m2 and provided the RR for incident gout.
All articles conducted multivariate analysis; two risk
estimates were included from the article by Bhole et al.
[15] which reported RRs separately for men and women.
The pooled unadjusted/age-adjusted RR of incident
gout in obese individuals compared with non-obese
Table 1 Characteristics of the included articles (n = 14) (Continued)
Article Country Study setting
(study name)
Age
(years)
Gender Ethnicity Years of
follow-up
Ascertainment of exposure Ascertainment of gout
diagnosis
et al.
(2012) [20]
(ARIC) 45–64;
mean 54,
SD 5.7
women:
3344 (58%)
black: 1791
(31%)
Wilson
et al.
(2014) [21]
USA Population
based
(health
insurance
database)
18–89 Men: 1449
(48%);
women:
1584 (52%)
– Up to 12 Diuretics: record linkage,
chlorthalidone vs
hydrochlorothiazide
Record linkage: ICD-9
for gout or allopurinol,
febuxostat, colchicine,
probenecid
Pan et al.
(2015) [22]a
Singapore Population
based
(Singapore
Chinese
health
study)
Hyp. 61.3
(median);
no Hyp.
59.3
(median)
Hyp. men:
4403
(40.7%);
no Hyp.
men: 7982
(40.4)
– 12 Hypertension: self-report
at recruitment interview
Self-report and clinical
verification
Burke et al.
(2016) [23]a
USA Population
based
(ARIC)
≥ 65 No gout
(n = 6535):
men 43.4%;
gout
(n = 230):
men 52.2%
White:
100%
25 Hypertension: SBP ≥
140 mmHg or DBP ≥
90 mmHg, or use of a
medication to treat
hypertension
Diuretic use: self-report
of medication use
Self-report
ARIC Atherosclerosis Risk In Communities, ACR American College of Rheumatology, BMI body mass index, CLUE (Give us a Clue to Cancer) II study, DBP
diastolic blood pressure, GP general practitioner, Hyp. hypertension, ICD-9 International Classification of Diseases, ninth revision, MSU monosodium
urate, SBP systolic blood pressure, SD standard deviation
aIncluded in meta-analysis (n = 7)
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Table 2 Risk estimates reported by included articles (n = 14)
Risk factor Author and year Sample
size
Cases of
incident
gout
Outcome
measure
Exposure Risk estimate
Minimal adjustment
model
Maximal
adjustment model
Obesity Choi et al. (2005) [14]a 47,150 730 RR (95% CI) BMI ≥ 30 kg/m2 at age
21
2.14 (1.37–3.32)b 1.66 (1.06–2.60)1
Bhole et al. (2010) [15]a 1951 200 RR (95% CI) BMI ≥ 30 kg/m2 in men 3.50 (2.30–5.32)b 2.90 (1.89–4.44)2
2476 104 BMI ≥ 30 kg/m2 in
women
3.52 (2.16–5.72)b 2.74 (1.65–4.58)2
McAdams-DeMarco
et al. (2011) [16]a
15,533 517 RR (95% CI) BMI ≥ 30 kg/m2 at age
21
2.06 (1.38–3.07)c 1.82 (1.21–2.73)3
Maynard et al. (2012)
[17]a
6263 106 RR (95% CI) BMI ≥ 30 kg/m2 at age
25
4.30 (2.14–8.64)b 2.84 (1.33–6.09)4
Hypertension Prior et al. 1987 [10] 1705 46 OR (95%
CI)
Systolic blood pressure 0.03 (0.02–0.05) –
Diastolic blood pressure 0.05 (0.03–0.07) –
Roubenoff et al. (1991) [11]a 1271 60 RR (95% CI) Hypertension 2.70 (1.45–5.13) –
Hochberg et al. (1995) [12]a 923 60 RR (95% CI) Hypertension (incident) 3.78 (2.18–6.58) 3.20 (1.80–5.68)5
Grodzicki et al. (1997) [13]a 2128 45 RR (95% CI) Hypertension 3.93 (1.60–9.70) –
Choi et al. (2005) [14]a 47,150 730 RR (95% CI) Hypertension 3.07 (2.64–3.56)b 2.31 (1.96–2.72)6
Bhole et al. (2010) [15]a 1951 200 RR (95% CI) Hypertension—men 2.39 (1.73–3.29)b 1.59 (1.12–2.24)7
2476 104 Hypertension—women 2.91 (1.74–4.88)b 1.82 (1.06–3.14)7
Chen et al. (2012) [18]a 60,181 1341 HR (95% CI) Hypertension—men 1.74 (1.54–1.95)b 1.32 (1.17–1.48)8
72,375 265 Hypertension—women 2.11 (1.59–2.79)b 1.34 (1.02–1.77)8
McAdams-DeMarco et al.
(2012) [25]a
10,872 274 HR (95% CI) Hypertension
(time-varying)
2.87 (2.24–3.78) 2.00 (1.54–2.61)9
Pan et al. (2015) [22]a 31,137 163
201
HR (95% CI) Hypertension—men
Hypertension—women
-
-
1.67 (1.33–2.09)10
2.08 (1.66–2.60)10
Burke et al. (2016) [23]a 2956
3809
120
110
HR (95% CI) Hypertension—men
Hypertension—women
1.33 (0.84–2.09)
1.64 (1.02–2.64)
-
-
Diuretic use Grodzicki et al. (1997) [13]a 2128 45 RR (95% CI) Diuretic use (and raised
diastolic blood pressure)
6.25 (2.40–16.70) –
Choi et al. (2005) [14]a 47,150 730 RR (95% CI) Diuretic use 3.37 (2.75–4.12)b 1.77 (1.42–2.20)11
Bhole et al. (2010) [15]a 4427 304 RR (95% CI) Diuretic use in men 4.31 (3.06–6.08)b 3.41 (2.38–4.89)12
Diuretic use in women 3.23 (2.13–4.91) 2.39 (1.53–3.74)12
McAdams-DeMarco et al.
(2012) [20]
5789 225 HR (95% CI) Diuretic use 1.72 (1.32–2.25) 1.48 (1.11–1.98)13
Wilson et al. (2014) [21] 3033 43 Mean
number
of days
until
incident
gout
(SD, range)
Chlorthalidone
(CTD) vs
hydrochlorothiazide
(HCTZ)
CTD: 183.6
(105.44, 21–362);
HCTZ: 152.7
(107.60, 22–345)
–
Burke et al. (2016) [23] 2956
3809
120
110
HR (95% CI) Diuretic use in men
Diuretic use in women
1.58 (0.89–2.81)
1.83 (1.12–2.98)
-
-
BMI body mass index, CI confidence interval, RR relative risk, OR odds ratio, HR hazard ratio, SD standard deviation
aIncluded in meta-analysis (n = 11)
bAge-adjusted model
cAge and sex-adjusted model
1–13Maximal adjustment model outlined for each article in each risk factor (adjustment for other risk factor of interest highlighted in italics)
as follows:
Maximal adjustment models within obesity articles:
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individuals was 2.84 (95% CI 2.15–3.76). The corre-
sponding pooled multivariate-adjusted RR was 2.24 (1.
76–2.86). There was no evidence of any statistically sig-
nificant heterogeneity between the risk estimates as
reflected by the low I2 values and non-significant p value
(I2 = 21.4%, p = 0.278) (Fig. 2).
Hypertension
For hypertension, 10 articles met the inclusion criteria;
of these, five provided RRs and four provided HRs which
were suitable for pooling. For the RR meta-analysis, all
five articles provided unadjusted/age-adjusted RRs, but
only three articles provided multivariate-adjusted RRs.
1Age, total energy intake, diuretic use, history of hypertension, presence of chronic renal failure, meat intake, seafood intake, purine-rich
vegetable intake, dairy food intake,
alcohol intake, meat intake and fluid intake
2Age, education level, alcohol consumption, hypertension, diuretic use, blood glucose level, cholesterol levels and menopausal status
(women only)
3Age, sex, alcohol intake, blood pressure, cholesterol and treatment for hypertension and hypercholesterolaemia
4Age, menopausal status, race, diabetes mellitus, hypertension, diuretic use, alcohol intake, organ meat intake and estimated glomerular
filtration rate
Maximal adjustment model within hypertension articles:
5Ethnicity and BMI
6Age, total energy intake, diuretic use, BMI, presence of chronic renal failure, meat intake, seafood intake, purine-rich vegetable intake, dairy
food intake, alcohol
intake, meat intake and fluid intake
7Age, education level, alcohol consumption, diuretic use, blood glucose level, cholesterol levels and menopausal status (women only)
8Age, obesity (BMI ≥ 27 kg/m2), hyperlipidaemia, diabetes mellitus, alcohol drinking and cigarette smoking
9Sex, race, BMI, alcohol intake and categorical estimated glomerular filtration rate
10Age, sex, dialect, year of interview, educational level, BMI, physical activity, smoking status, alcohol use and history of diabetes at follow-up I
Maximal adjustment models within diuretic use articles:
11Age, total energy intake, BMI, history of hypertension, presence of chronic renal failure, meat intake, seafood intake, purine-rich vegetable
intake, dairy food
intake, alcohol intake, meat intake and fluid intake
12Age, education level, BMI, alcohol consumption, hypertension, blood glucose level, cholesterol levels and menopausal status (women only)
13Sex, race, baseline BMI, categorical glomerular filtration rate and time-varying blood pressure
NOTE: Weights are from random effects analysis
.
.
Unadjusted/Age-adjusted
Choi et al.
Bhole et al.
Bhole et al.
McAdams-DeMarco et al.
Maynard et al.
Subtotal  (I-squared = 43.4%, p = 0.133)
Maximally-adjusted
Choi et al.
Bhole et al.
Bhole et al.
McAdams-DeMarco et al.
Maynard et al.
Subtotal  (I-squared = 21.4%, p = 0.278)
Article
2005
2010
2010
2011
2012
2005
2010
2010
2011
2012
Year
Men (BMI 30 at age 21)
Men (BMI 30)
Women (BMI 30)
Men and women (BMI 30 at age 21)
Women (BMI 30 at age 25)
Men (BMI
Men (BMI 30)
30 at age 21)
Women (BMI 30)
Men and women (BMI
Women (BMI 30 at age 25)
30 at age 21)
Gender
47,150
1,951
2,476
15,533
6,263
47,150
1,951
2,476
15,533
6,263
n
2.14 (1.37, 3.32)
3.50 (2.30, 5.32)
3.52 (2.16, 5.72)
2.06 (1.38, 3.07)
4.30 (2.14, 8.64)
2.84 (2.15, 3.76)
1.66 (1.06, 2.60)
2.90 (1.89, 4.44)
2.74 (1.65, 4.58)
1.82 (1.21, 2.73)
2.84 (1.33, 6.09)
2.24 (1.76, 2.86)
Risk (95% CI)
Relative
21.63
22.90
19.43
24.01
12.03
100.00
22.41
24.13
18.31
25.91
9.24
100.00
Weight
%
1 10
Fig. 2 Forest plot showing pooled risk estimates for incident gout associated with body mass index ≥ 30 kg/m2. BMI body mass index, CI
confidence interval
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The pooled unadjusted/age-adjusted RR for incident
gout in hypertensive individuals was almost three times
higher than that in normotensive individuals (RR 2.98
(95% CI 2.63–3.37)). On pooling multivariate RRs, this
risk was reduced, but remained significant (2.11 (1.64–2.
72)). There was no evidence of any statistically signifi-
cant heterogeneity between the risk estimates (I2 = 48.
3%, p = 0.122) (Fig. 3). For the HR meta-analysis, three
articles provided unadjusted/age-adjusted HRs [18, 23, 25]
and three provided multivariate-adjusted HRs [18, 22, 25].
The pooled unadjusted/age-adjusted HR for incident gout
in hypertensive individuals was almost two times higher
than that in normotensive individuals (RR 1.93 (95% CI 1.
52–2.46)). On pooling multivariate HRs, this risk was
reduced, but remained significant (1.64 (1.34–2.01)). How-
ever, heterogeneity was reported as statistically significant
(I2 = 78.6%, p = 0.001) (Fig. 4).
Diuretic use
Three of the six articles which met the inclusion cri-
teria for diuretic use were suitable for inclusion in the
meta-analysis. Only two studies provided multivariate-
adjusted RRs suitable for pooling; however, these stud-
ies provided three relevant adjusted risk estimates. The
pooled unadjusted/age-adjusted RR of incident gout in
people taking diuretics compared to those not taking
diuretics was 3.59 (95% CI 3.06–4.21). The correspond-
ing pooled adjusted RR was 2.39 (1.57–3.65). Evidence
for statistically significant heterogeneity was identified
for the pooled multivariate-adjusted RRs (I2 = 79.1%,
p = 0.008), but not for the unadjusted/age-adjusted RRs
(I2 = 0.0%, p = 0.397) (Fig. 5).
Discussion
This systematic review and meta-analysis of cohort
studies has shown that in primary care and general
populations, obesity, hypertension and diuretic use are
all independent risk factors for incident gout. Each of
these more than doubled the risk of developing gout.
Although this is the first meta-analysis of hypertension
as a risk factor for gout, our findings for the other risk
factors of obesity and diuretic use are supported by
previous reviews. Our findings concerning obesity are
consistent with those of a recent systematic review and
meta-analysis which found that increasing BMI was a
risk factor for the development of gout [26]. However, in
contrast to our research, this meta-analysis included
case–control studies as well as cohort studies, and
NOTE: Weights are from random effects analysis
.
.
Unadjusted/Age-adjusted
Roubenoff et al.
Hochberg et al.
Grodzicki et al.
Choi et al.
Bhole et al.
Bhole et al.
Subtotal  (I-squared = 0.0%, p = 0.679)
Maximally-adjusted
Hochberg et al.
Choi et al.
Bhole et al.
Bhole et al.
Subtotal  (I-squared = 48.3%, p = 0.122)
Article
1991
1995
1997
2005
2010
2010
1995
2005
2010
2010
Year
Men
Men
Men and women
Men
Men
Women
Men
Men
Men
Women
Gender
1,271
923
2,128
47,150
1,951
2,476
923
47,150
1,951
2,476
n
2.70 (1.45, 5.13)
3.78 (2.18, 6.58)
3.93 (1.60, 9.70)
3.07 (2.64, 3.56)
2.39 (1.73, 3.29)
2.91 (1.74, 4.88)
2.98 (2.63, 3.37)
3.20 (1.80, 5.68)
2.31 (1.96, 2.72)
1.59 (1.12, 2.24)
1.82 (1.06, 3.14)
2.11 (1.64, 2.72)
Risk (95% CI)
Relative
3.84
5.03
1.89
68.63
14.85
5.77
100.00
14.19
43.73
26.67
15.41
100.00
Weight
%
1 10
Fig. 3 Forest plot showing pooled risk estimates (relative risk) for incident gout associated with hypertension. CI confidence interval
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included some studies of populations with hyperuricae-
mia, who are at greater risk of gout than the general
population, perhaps explaining higher relative risks than
those seen in our study. Hueskes et al. [8] published a
systematic review examining the risk of gout associ-
ated with diuretics. They concluded that there was a
trend that patients using either loop or thiazide di-
uretics were at an increased risk of gout; however,
they reported that the magnitude and independence
of this association in different studies was inconsist-
ent and that evidence to support stopping diuretics in
those with gout was lacking [8]. An important consid-
eration is that their outcome was specifically defined
as ‘acute gouty arthritis’ or ‘chronic tophaceous gout’,
which is in contrast to the more inclusive outcome
used in this study which was incident gout. This pre-
vious study did not attempt to pool risk estimates
from different studies and was therefore unable to
quantify the risk incurred by diuretic use. This sys-
tematic review also included randomised controlled
trials, cohort studies and case–control studies,
whereas our review included only cohort studies.
We have shown that obesity, hypertension and diuretic
use are all important risk factors for incident gout. The
prevalence of obesity is rising within the UK as well as
globally and it has been linked to co-morbidities and mor-
tality; as a result, the obesity epidemic has become a major
public health concern. Previous research has demonstrated
the benefits of weight reduction interventions in prevent-
ing gout [27] and our study has added further evi-
dence to the need to tackle obesity due to its strong
association with gout. Hypertension is primarily man-
aged in primary care; careful selection of therapeutic
agents can help to reduce the risk of future gout.
This study also suggests that diuretics should be
avoided in those at risk of developing gout, where
possible, and alternatives considered.
Our study had a number of strengths including the
comprehensive search strategy and literature review
process, with no restrictions on language. By consider-
ing only primary care and population-based cohort
studies for inclusion, we ensured that the results would
be generalisable to most patients with gout, who are
managed exclusively in primary care. We only included
cohort studies in our review, reducing the effect of
recall bias frequently encountered in case–control
studies and allowing certainty of any temporal relation-
ships between exposure and outcome [28]. Finally, as
the risk estimates included in the meta-analyses were ad-
justed for the other risk factors of interest (i.e. obesity
NOTE: Weights are from random effects analysis
.
.
Unadjusted/Age-adjusted
Chen et al.
Chen et al.
McAdams-DeMarco et al.
Burke et al.
Burke et al.
Subtotal  (I-squared = 73.1%, p = 0.005)
Maximally-adjusted
Chen et al.
Chen et al.
McAdams-DeMarco et al.
Pan et al.
Pan et al.
Subtotal  (I-squared = 78.6%, p = 0.001)
Article
2012
2012
2012
2016
2016
2012
2012
2012
2015
2015
Year
Men
Women
Men and women
Men
Women
Men
Women
Men and women
Men
Women
Gender
1341
265
274
120
110
1341
265
274
163
201
n
1.74 (1.54, 1.95)
2.11 (1.59, 2.79)
2.87 (2.24, 3.78)
1.33 (0.84, 2.09)
1.64 (1.02, 2.64)
1.93 (1.52, 2.46)
1.32 (1.17, 1.48)
1.34 (1.02, 1.77)
2.00 (1.54, 2.61)
1.67 (1.33, 2.09)
2.08 (1.66, 2.60)
1.64 (1.34, 2.01)
Ratio (95% CI)
Hazard
28.13
21.35
22.22
14.47
13.83
100.00
24.20
17.75
18.24
19.87
19.94
100.00
Weight
%
1 10
Fig. 4 Forest plot showing pooled risk estimates (hazard ratios) for incident gout associated with hypertension. CI confidence interval
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estimates were adjusted for hypertension, hypertension es-
timates were adjusted for diuretic use, etc.), we are
confident these risk estimates are independent. As a re-
sult, it appears that hypertension is a risk factor for gout
independent of diuretic use, but none of the included
studies adjusted for other anti-hypertensive drugs which
can cause hyperuricaemia. Therefore, we were unable to
investigate whether the effect of hypertension was also in-
dependent of these.
Limitations in our work include that some studies had
used specific samples (e.g. health professionals, univer-
sity students), meaning their sampling frames with lower
social deprivation are likely to underestimate the risk of
incident gout. Other limitations include, firstly, that one-
quarter of the articles did not specifically indicate that
they had excluded individuals with a previous diagnosis
of gout and, secondly, that variation may exist between
pooled multivariate relative risks due to adjustments for
different factors within different studies. However, re-
garding this latter point, several factors were the same
(e.g. age, gender) and the majority of articles adjusted
for the most important factors (in the case of this re-
view, BMI, hypertension and/or diuretic use). In relation
to this, although we are confident on the role of risk for
each of these three variables, we are unable to address
risk through different interactions of these, which would
be clinically useful. Finally, diagnosis of gout was
predominantly determined through self-report as no
study required gout to be defined using the gold stand-
ard of crystal visualisation in the synovial fluid. This
raises the possibility of misclassification; however, this
approach is not unusual in large population/primary
care-based epidemiological studies.
Conclusion
Obesity, hypertension and diuretic use are all risk factors
for incident gout, independent of one another and each
more than doubling the risk of developing gout com-
pared with those without these conditions. Such patients
should be recognised by clinicians as being at greater
risk of developing gout and provided with appropri-
ate management and treatment options. Future re-
search into interactions between these individual risk
factors would expand our understanding of the epi-
demiology and pathophysiology of gout. As diuretic
use in hypertensive patients is likely and a large pro-
portion of such patients will be overweight, future
research should consist of prospective studies which
consider the interaction between co-morbidities and
examine how certain clusters of co-morbidities influ-
ence the risk of developing gout, building on the
work of Richette et al. [29].
NOTE: Weights are from random effects analysis
.
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Grodzicki et al.
Choi et al.
Bhole et al.
Bhole et al.
Subtotal  (I-squared = 0.0%, p = 0.397)
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Choi et al.
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1997
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Men
Women
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n
6.25 (2.40, 16.70)
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3.23 (2.13, 4.91)
3.59 (3.06, 4.21)
1.77 (1.42, 2.20)
3.41 (2.38, 4.89)
2.39 (1.53, 3.74)
2.39 (1.57, 3.65)
Risk (95% CI)
Relative
2.67
61.56
21.34
14.42
100.00
38.40
32.66
28.95
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%
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Fig. 5 Forest plot showing pooled risk estimates for incident gout associated with diuretic use. CI confidence interval
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Appendix 1 Appendix 2
Table 3 Search Strategy
Gout search terms
exp Gout/
gout*.ti,ab.
podagra.ti,ab.
toph*.ti,ab.
MeSH descriptor: [Gout] explode all trees (Cochrane search only)
Obesity search terms
exp Obesity/
obes*.ti,ab.
Body Mass Index/
BMI.ti,ab.
MeSH descriptor: [Obesity] explode all trees (Cochrane search only)
MeSH descriptor: [Body Mass Index] this term only (Cochrane search
only)
Hypertension search terms
exp Hypertension/
hypertens*.ti,ab.
(blood adj3 pressure).ti,ab.
MeSH descriptor: [Hypertension] this term only (Cochrane search only)
Diuretics search terms
exp Diuretics/
(loop adj3 diuretic*).ti,ab.
(high-ceiling adj3 diuretic*).ti,ab.
MeSH descriptor: [Diuretics] explode all trees (Cochrane search only)
Table 4: Articles reviewed in full, but subsequently excluded
(n=35)
Author Year Article title Reason for
exclusion
Ogryzlo 1960 The renal factor in the etiology of
primary gout
Not cohort
Mertz &
Schindera
1968 Secondary gout six years after
acute renal failure
Not cohort
De Muckadall &
Gyntelberg
1976 Occurrence of gout in Copenhagen
males aged 40-59
Gout not an
outcome
Seidell et al 1985 Fat distribution of overweight persons
in relation to morbidity and subjective
health
Gout not an
outcome
Tsitlanadze et al 1987 Incidence and various risk factors for
gout in the Georgian SSR
Not cohort
Van Noord et al 1990 The relationship between fat
distribution and some chronic diseases
in 11,825 women participating in the
DOM-project
Gout not an
outcome
Hoiberg &
McNally
1991 Profiling overweight patients in the
US Navy: Health conditions and costs
Based on
RCT
Scott & Higgens 1992 Diuretic induced gout: A multifactorial
condition
Not cohort
Youssef et al 1995 Does renal impairment protect from
gout?
Not cohort
Gurwitz et al 1997 Thiazide diuretics and the initiation
of anti-gout therapy
Not cohort
Lin et al 2000 Community based epidemiological
study on hyperuricemia and gout
in Kin-Hu, Kinmen
Not general
population
Lin et al 2000 The interaction between uric acid
level and other risk factors on the
development of gout among
asymptomatic hyperuricemic men
in a prospective study
Not cohort
Takahashi et al 2000 Increased visceral fat accumulation
in patients with primary gout
Not cohort
Lin et al 2006 Association of obesity and chronic
disease in Taiwan
Not cohort
Miao et al 2008 Dietary and lifestyle changes associated
with high prevalence of hyperuricemia
and gout in the Shandong coastal cities
of Eastern China
Not cohort
Zhu et al 2010 The serum urate-lowering impact of
weight loss among men with a high
cardiovascular risk profile: the Multiple
Risk Factor Intervention Trial
Not cohort
Barskova et al 2011 Main factors of gender dimorphism of
gout (estrogens and diuretics vs alcohol
and genetics)
Not cohort
Chang 2011 Dietary intake and the risk of
hyperuricemia, gout and chronic
kidney disease in elderly Taiwanese
men
Not cohort
Kawashima et al 2011 Association between asymptomatic
hyperuricemia and new-onset chronic
kidney disease in Japanese male
workers: a long-term retrospective
cohort study
Gout not an
outcome
Primatesta et al 2011 Gout not an
outcome
Evans et al. Arthritis Research & Therapy  (2018) 20:136 Page 11 of 15
Table 4: Articles reviewed in full, but subsequently excluded
(n=35) (Continued)
Author Year Article title Reason for
exclusion
Gout treatment and comorbidities:
A retrospective cohort study in a
large US managed care population
Lin et al 2012 Prevalence of hyperuricemia and its
association with antihypertensive
treatment in hypertensive patients
in Taiwan
Not cohort
Chen et al 2013 Impact of obesity and
hypertriglyceridemia on gout
development with or without
hyperuricemia: A prospective
study
Not cohort
Krishnan 2013 Chronic kidney disease and the
risk of incident gout among
middle-aged men: a seven-year
prospective observational study
Not cohort
Lin et al 2013 The association of anthopometry
indices with gout in Taiwanese
men
Not cohort
McAdams-
DeMarco et al
2013 A urate gene-by-diuretic interaction
and gout risk in participants with
hypertension: results from the
ARIC study
Not cohort
Ozturk et al 2013 Demographic and clinical features
of gout patients in Turkey:
a multicenter study
Not general
population
Wang et al 2013 Risk factors for gout developed
from hyperuricemia in China:
a five-year prospective cohort
study
Not general
population
Lu et al 2014 Contemporary epidemiology of
gout and hyperuricemia in
community elderly in Beijing
Gout not an
outcome
Pan et al 2015 Bidirectional association between
hypertension and gout:
The Singapore chinese health
study
Not cohort
Wang et al 2015 Chronic kidney disease as a risk
factor for incident gout among
men and women: retrospective
cohort study using data from
the Framingham Heart Study
Not general
population
Abeles et al 2015 Hyperuricemia, gout, and
cardiovascular disease: an
update
Not cohort
Bao et al 2015 Lack of gene-diuretic interactions
on the risk of incident gout: the
Nurses' Health Study and Health
Professionals Follow-up Study
Not general
population
Jing et al 2015 Prevalence and correlates of gout
in a large cohort of patients with
chronic kidney disease: the
German Chronic Kidney Disease
(GCKD) study
Not general
population
Dalbeth et al 2015 Body mass index modulates the
relationship of sugar-sweetened
beverage intake with serum
urate concentrations and gout
Not cohort
Drivelegka et al 2016 Comorbidity pattern at the time
of gout diagnosis: A population-
Not cohort
Table 4: Articles reviewed in full, but subsequently excluded
(n=35) (Continued)
Author Year Article title Reason for
exclusion
and register-based case-control
study from Western Sweden
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Appendix 3
Table 5: Quality appraisal scores of articles included in meta-analysis using the Newcastle-Ottawa Scale (NOS)
Article Selection Comparability Outcome
1 2 3 4 1 1 2 3
Is exposed cohort
representative?
How was non-
exposed cohort
selected?
How was exposed
cohort selected?
Clear, outcome
wasn’t present?
Are cohorts
compatible?
How was
outcome
assessed?
Was follow-up
long enough?
Adequate cohort
sample followed-up?
Roubenoff et al.
1991
C A* A* B A*, B* B* A* B*
Hochberg et al.
1995
C B D B A*, B* B* A* B*
Grodzicki et al.
1997
B* A* A* B - B* B D
Choi et al. 2005 C A* C A* A*, B* B* A* B*
Bhole et al. 2010 A* A* A* A* A*, B* B* A* B*
McAdams-
DeMarco et al.
2011
A* A* C A* A*, B* C A* B*
Maynard et al.
2012
B* A* A* A* A*, B* C A* B*
Chen et al. 2012 A* A* A* A* A*, B* B* A* B*
McAdams-
DeMarco et al.
2012
B* A* A* A* A*, B* C A* B*
Pan et al. 2015 A* A* B* A* A*, B* C A* D
Burke et al. 2016 B* A* A* A* A*, B* C A* D
A indicates the highest methodological quality whereas D indicates the worst quality; An asterisk (*) denotes that the article has scored highest for that
particular criterion. A comma (,) separating two scores denotes that an article i) matched exposed and non-exposed and ii) adjusted for potential
confounding factors
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Appendix 4
Abbreviations
ARIC: Atherosclerosis Risk In Communities; BMI: Body mass index;
CI: Confidence interval; HR: Hazard ratio; MeSH: Medical subject headings;
NOS: Newcastle–Ottawa Scale; OR: Odds ratio; RR: Risk ratio; ULT: Urate
lowering therapies
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